Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication

Table 2 Univariate and multivariate analyses for factors associated with hepatocellular carcinoma development

Variables	HR (95%CI)	P value
Univariate analysis
Age (by each year)	1.04 (0.31-1.11)	0.347
Male sex	1.61 (0.32-8.04)	0.564
BMI (by each kg/m2)	1.00 (0.80-1.25)	0.982
Habitual drinker	1.26 (0.25-6.27)	0.775
Diabetes mellitus	5.58 (1.19-26.21)	0.030
HCV-RNA (by each logIU/mL)	0.87 (0.44-1.72)	0.696
HCV genotype 1	2.90 (0.58-14.35)	0.195
Stage of fibrosis	3.59 (1.68-7.68)	0.001
Grade of inflammation	4.32 (1.02-18.40)	0.048
Albumin (by each g/dL)	0.03 (0.00-0.29)	0.003
ALT (by each IU/L)	1.00 (1.00-1.01)	0.196
Platelet count (by each 104/mL)	0.75 (0.63-0.90)	0.002
GGT (by each IU/L)	1.00 (1.00-1.01)	0.452
AFP (by each ng/mL)	1.00 (1.00-1.00)	0.033
PI use	2.93 (0.31-27.70)	0.347
AKR1B10 (by each %)	1.06 (1.03-1.10)	< 0.001
Multivariate analysis
AKR1B10 (by each %)	1.04 (1.03-1.10)	0.001

AFP: α-fetoprotein; AKR1B10: Aldo-keto reductase family1 member B10; ALT: Alanine aminotransferase; BMI: Body mass index; GGT: γ-glutamyl transpeptidase; HCV: Hepatitis C virus; PI: Protease inhibitor.